[1] The second fact reframes the whole pairing
While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said
Richardson TG, Wang Q, Sanderson E, Mahajan A, McCarthy MI, Frayling TM, et al
Pregnant or breastfeeding women are also advised against taking lipotropic injections, as the safety of these treatments during pregnancy and lactation has not been conclusively established
Cerebrospinal fluid and serum markers of inflammation in autism
Youll add some basic health information, too